Velcade (bortezomib) is neither traditional chemotherapy nor immunotherapy. It belongs to a class called proteasome inhibitors, which is a form of targeted therapy. Unlike conventional chemotherapy, which kills rapidly dividing cells throughout the body, Velcade zeroes in on a specific cellular recycling system that cancer cells depend on to survive. And unlike immunotherapy, which trains or unleashes the immune system to attack cancer, Velcade works by directly disrupting the internal machinery of cancer cells.
How Velcade Actually Works
Every cell in your body contains a structure called a proteasome, essentially a garbage disposal for proteins. When proteins are damaged or no longer needed, the proteasome breaks them down so the cell can function properly. Cancer cells rely on this system even more heavily than normal cells because they produce large amounts of abnormal proteins that need constant clearing.
Velcade blocks this protein recycling system by binding directly to the proteasome complex and shutting down its activity. When the garbage disposal stops working, damaged and unwanted proteins pile up inside the cancer cell. This buildup triggers a cascade of events: it shuts down a key survival signal that cancer cells use to resist death, cuts off signals that help tumors grow new blood vessels, and ultimately pushes the cancer cell into programmed self-destruction. Importantly, this blocking action is reversible. Once the drug clears the body, proteasome function resumes in healthy cells, which is part of why normal cells can recover between treatment cycles.
Why It Gets Confused With Chemotherapy
Velcade is often lumped in with chemotherapy for a practical reason: it’s a powerful anticancer drug given on a schedule of treatment cycles, and it causes side effects that overlap with traditional chemo, including low blood counts and nausea. In clinical trials, about 36% of patients developed low platelet counts and 17% experienced low white blood cell counts. Digestive side effects were even more common, with nausea affecting roughly 55% of patients, diarrhea 52%, constipation 41%, and vomiting 33%.
These numbers can make the treatment feel a lot like chemo from the patient’s perspective. But the mechanism is fundamentally different. Traditional chemotherapy drugs damage DNA or interfere with cell division in all rapidly growing cells, which is why they cause widespread collateral damage to hair follicles, the gut lining, and bone marrow. Velcade targets a specific protein-recycling pathway that cancer cells are uniquely dependent on, making it a targeted therapy even though some of its side effects overlap with older drugs.
Why It’s Not Immunotherapy Either
Immunotherapy works by activating or directing the immune system to recognize and destroy cancer. Checkpoint inhibitors, for example, remove the “brakes” that prevent immune cells from attacking tumors. CAR-T cell therapy engineers a patient’s own immune cells to hunt cancer. Velcade does neither of these things. Its primary job is to directly kill cancer cells by disrupting their internal protein management.
That said, research has shown Velcade can have secondary effects on the immune system. In lab studies, it made tumor cells more visible to killer T cells by increasing certain surface markers that immune cells use to identify targets. It also appeared to support T cell function rather than suppress it. These immune-related effects are a secondary bonus, not the drug’s core purpose, and they don’t make it an immunotherapy in any clinical sense.
What Velcade Is Approved to Treat
The FDA has approved Velcade for two cancers: multiple myeloma (a blood cancer that forms in the bone marrow) and mantle cell lymphoma (a type of non-Hodgkin lymphoma). In multiple myeloma, it is used both as a frontline treatment and for patients whose cancer has returned after previous therapy.
Current national treatment guidelines list Velcade as a core component of the most recommended first-line regimens for multiple myeloma. It is typically combined with other drugs, often an immunomodulatory drug and a monoclonal antibody, in three- or four-drug combinations. It can also be used on its own as maintenance therapy for patients who can’t tolerate other options.
What Treatment Looks Like
Velcade is most commonly given as a subcutaneous injection, meaning a shot just under the skin, rather than through an IV. Subcutaneous delivery is the preferred route because it’s faster, more convenient, and associated with somewhat lower rates of nerve-related side effects. In clinical trials, peripheral neuropathy (tingling, numbness, or pain in the hands and feet) occurred in about 41% of patients receiving subcutaneous injections compared to 48% with IV delivery.
A standard cycle runs 21 days. Treatment is typically given on days 1, 4, 8, and 11, followed by a 10-day rest period before the next cycle begins. However, weekly dosing (rather than twice-weekly) has become preferred in many settings because the twice-weekly schedule carries a higher risk of neuropathy, which can force treatment delays or early discontinuation. Peripheral neuropathy is the side effect most specific to Velcade and the one that most often limits how long patients can stay on the drug.
Where It Fits Among Cancer Drugs
Cancer treatment today falls into several broad categories. Traditional chemotherapy kills fast-growing cells indiscriminately. Targeted therapies like Velcade block specific molecular pathways that cancer cells depend on. Immunotherapies harness the immune system. Immunomodulatory drugs, like lenalidomide, have both direct anticancer and immune-stimulating properties. Monoclonal antibodies can work as targeted therapy, immunotherapy, or both, depending on their design.
Velcade sits firmly in the targeted therapy category. When your oncology team discusses your treatment plan and mentions Velcade alongside drugs from other categories, it helps to know that each drug in the combination is attacking the cancer through a different mechanism. That’s precisely the point of combining them: hitting the cancer from multiple angles at once.